Retrospective Study About Nasopharyngeal Carcinoma at C. S. Parc Tauli

July 31, 2015 updated by: Yolanda Escamilla-Carpintero, Corporacion Parc Tauli

Retrospective study of patients diagnosed with a nasopharyngeal carcinoma included in our data base care between June 1990 and September 2013.

Our hypothesis is:

Our series of patients with a history of nasopharyngeal carcinoma presents epidemiological, response rates to the different treatments and survival similar to those described in the literature

Study Overview

Status

Completed

Conditions

Detailed Description

Retrospective study of 50 patients diagnosed with nasopharyngeal carcinoma. The following variables will be studied: age, sex, toxic habits , associated pathology, patient origin , first symptom , duration , histology, stage , second malignancies , recurrences , metastases , treatments performed , the response thereto and survival.

Study Type

Observational

Enrollment (Actual)

50

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Spain
    • Barcelona
      • Sabadell, Barcelona, Spain, 08208
        • Corporació Sanitària Parc Taulí

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients diagnosed of Nasopharyngeal Carcinoma at Ear-Nose-Throught Department at Corporació Sanitària Parc Taulí from 1993 to 2013

Description

Inclusion Criteria:

  • Patients diagnosed of Nasopharyngeal Carcinoma at Ear-Nose-Throat Department at Corporació Sanitària Parc Taulí from 1993 to 2013

Exclusion Criteria:

  • None

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Nasopharyngeal Carcinoma

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Description of Nasopharyngeal Carcinoma Patients
Time Frame: 1 year after diagnostic
Describe our population diagnosed nasopharyngeal carcinoma and compared in epidemiology and therapeutic results with those in the literature
1 year after diagnostic

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Corporacion Parc Tauli

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2014

Primary Completion (Actual)

October 1, 2014

Study Completion (Actual)

October 1, 2014

Study Registration Dates

First Submitted

July 23, 2014

First Submitted That Met QC Criteria

July 23, 2014

First Posted (Estimate)

July 24, 2014

Study Record Updates

Last Update Posted (Estimate)

August 3, 2015

Last Update Submitted That Met QC Criteria

July 31, 2015

Last Verified

July 1, 2015

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CPT_ORL14_YE1

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Nasopharyngeal Carcinoma

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Singapore

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe